Skip to main content
SpringerLink
Log in
Book cover

Platinum-Based Drugs in Cancer Therapy pp 171–194Cite as

Clinical Experience with Cisplatin and Carboplatin

  • Chapter

  • 309 Accesses

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

Abstract

Malignant disease is a major cause of mortality, killing approximately 25% of individuals in the Western world. The most common cancers are those originating in the lung, breast, colon, and rectum (1). Improvements in curability and survival are dependent on advances in early detection, surgery, radiotherapy, and chemotherapy, but once widespread metastatic disease has become established chemotherapy is a central component of management. The era of chemotherapy commenced in the late 1940s and 1950s with the clinical introduction of the classical alkylating agents (e.g., nitrogen mustard, cyclophosphamide and melphalan), and antimetabolites [e.g., methotrexate and 5-fluorouracil (5-FU)], with a marked improvement in the treatment of lymphomas and leukemias. The next major advance was the appearance of cisplatin in 1972. Over the last 25 years the use of cisplatin and its less toxic analog carboplatin has influenced the chemotherapeutic management of many common solid tumors. As a result, metastatic germ cell tumors are now curable (Fig. 1), and the outlook for patients with ovarian cancer and certain childhood tumors has improved significantly.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Office for National Statistics. (1997). The Health of Adult Britain 1841–1994. Office for National Statistics, London, Vol. 2, Chapter 17, pp. 30–59.

    Google Scholar 

  2. Gaynon, P. S., Ettinger, L. J., Baum, E. S., (1990) Carboplatin in childhood brain tumours: a Childrens Cancer Study group phase II trial. Cancer 66, 2465–2469

    Article  PubMed  CAS  Google Scholar 

  3. Calvert, A. H., Newell, D. R., Gumbrell, L. A., (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol. 7, 1748–1756.

    PubMed  CAS  Google Scholar 

  4. Jodrell, D. I., Egorin, M. J., Canetta, R. M., (1992) Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J. Clin. Oncol. 10, 520–528.

    Google Scholar 

  5. Pinkerton, C. R., Broadbent, V., Horwich, A., (1990) “JEB”—a carboplatin based regimen for malignant germ cell tumours in children. Br. J. Cancer 62, 257–262.

    Google Scholar 

  6. Cockcroft, D. W. and Gault, M. H. (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16, 31–41.

    Article  PubMed  CAS  Google Scholar 

  7. Smit, E. F., Willemse, P. H. B., Sleijfer, D. T. (1991) Continuous infusion carboplatin on a 21-day schedule: a phase I and pharmacokinetic study. J. Clin. Oncol. 9, 100–110.

    PubMed  CAS  Google Scholar 

  8. Einhorn, L. H. and Donohue, J. D. (1977) Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann. Intern. Med. 87, 293–298.

    PubMed  CAS  Google Scholar 

  9. Horwich, A., Sleijfer, D. T., Fossa, S. D., Kaye, S. B., Oliver, R. T. D., Cullen, M. H., (1997) Randomised trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a multiinstitutional Medical Research Council/European Organisation for Research and Treatment of Cancer trial. J. Clin. Oncol. 15, 1844–1852.

    PubMed  CAS  Google Scholar 

  10. Childs W. J., Nicholls J., Horwich A. (1992) The optimisation of carboplatin dose in carboplatin, etoposide and bleomycin combination chemotherapy for good prognosis metastatic nonseminomatous germ cell tumours of the testis. Ann. Oncol. 3, 291–296.

    PubMed  CAS  Google Scholar 

  11. Bajorin, D. F., Sarosdy, M. F., Pfister, D. G., Mazumdar, M., Motzer, R. J., Scher, H. I., (1993) Randomised trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J. Clin. Oncol. 11, 598–606.

    PubMed  CAS  Google Scholar 

  12. Peckham, M. J., Horwich, A., and Hendry, W. F. (1985) Advanced seminoma: treatment with cis-platinum based combination chemotherapy or carboplatin (JM8). Br. J. Cancer 52, 7–13.

    Article  PubMed  CAS  Google Scholar 

  13. Oliver, R. T., Edmonds, P. M., Ong, J. Y., (1994) Pilot studies of 2 and 1 course carboplatin as adjuvant for stage I seminoma: should it be tested in a randomised trial against radiotherapy? Int. J. Radiat. Oncol. Biol. Phys. 29, 3–8.

    Article  PubMed  CAS  Google Scholar 

  14. Advanced Ovarian Trialists Group. (1991) Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. BMJ 303, 884–893.

    Google Scholar 

  15. Calvert, A. H., Newell, D. R., Gore, M. E. (1992) Future directions with carboplatin: can therapeutic monitoring, high-dose administration, and hematologic support with growth factors expand the spectrum compared with cisplatin? Semin. Oncol. 19 (Suppl 2), 155–163.

    Google Scholar 

  16. Kaye, S. B., Paul, J., Cassidy, J., Lewis, C. R., Duncan, I. D., Gordon, H. K., (1996) Mature results of a randomised trial of two doses of cisplatin for the treatment of ovarian cancer. J. Clin. Oncol. 14, 2113–2119.

    Google Scholar 

  17. Murphy, D., Crowther, D., Renninson, J., (1993) A randomised dose intensity study in ovarian carcinoma comparing chemotherapy given at four week intervals for six cycles with half dose chemotherapy given for twelve cycles. Ann. Oncol. 4, 377–383.

    PubMed  CAS  Google Scholar 

  18. Ngan, H. Y., Choo, Y. C., Cheung, M., (1989) A randomised trial of high-dose vs low dose cisplatin combined with cyclophosphamide in the treatment of advanced ovarian cancer. Chemotherapy 35, 221–227.

    Article  PubMed  CAS  Google Scholar 

  19. McGuire, W. P., Hoskins, W. J., Brady, M. F., (1995) Assessment of dose intensive therapy in suboptimally debulked ovarian cancer: a Gynaecologic Oncology Group study. J. Clin. Oncol. 13, 1589–1599.

    PubMed  CAS  Google Scholar 

  20. Calvert, A. H. Lind, M. J., Ghazal-Aswad, S., Gumbrell, L., Millward, M. J., Bailey, N. P., (1994) Carboplatin and granulocyte colony-stimulating factor as first-line treatment for epithelial ovarian cancer: a phase I dose-intensity escalation study. Semin. Oncol. 21. (Suppl 12) 1–6.

    Google Scholar 

  21. Gore, M., Mainwaring, P., A’Hern, R., MacFarlane, V., Slevin, M., Harper, P. (1998) Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. J. Clin. Oncol. 16, 2426–2434.

    Google Scholar 

  22. Jakobsen, A., Bertelsen, K., Andersen, J. E., Haysteen, H., Jakobsen, P., Moeller, K. A., (1997) Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study. J. Clin. Oncol. 15 193–198.

    Google Scholar 

  23. Gore, M. E., Fryatt, I., Wiltshaw, E., Dawson, T. (1990) Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol. Oncol. 36, 207–211.

    Article  PubMed  CAS  Google Scholar 

  24. Alberts, D. S., Green, S., Hannigan, E.V., (1992) Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase III randomised trial in stages III and IV ovarian cancer. J. Clin. Oncol. 10, 706–717.

    PubMed  CAS  Google Scholar 

  25. Swenerton, K., Jeffrey, J., Stuart, G., (1992) Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomised phase III study of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 10, 718–726.

    PubMed  CAS  Google Scholar 

  26. Edmonson, J. H., McCormack, G. W., Wieand, H. S., (1989) Cyclophosphamidecisplatin versus cyclophosphamide-carboplatin in stage III-IV ovarian carcinoma: a comparison of equally myelosuppressive regimens. J. Natl. Cancer Inst. 81, 1500–1504.

    Google Scholar 

  27. Parmar, M. K. B., Torri, V., Bonaventura, A., Bonazzi, C., Colombo, N., Delaloye, J.-F., (1998) ICON 2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. Lancet. 352, 1571–1576.

    Article  Google Scholar 

  28. McGuire, W. P., Hoskins, W. J., Brady, M. F., Kugera, P.C., Partridge, E. E., Look, K. Y., (1996). Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in stage III and stage IV ovarian cancer. N. Engl. J. Med. 334, 1–6.

    Article  PubMed  CAS  Google Scholar 

  29. Stuart, G., Bertelsen, K., Mangioni, C., Trope, C., James, K., Cassidy, J., (1998) Updated analysis shows a highly significant improved overall survival (OS) for cisplatinpaclitaxel as first line treatment of advanced ovarian cancer: mature results of the EORTCGCCG, NOCOVA, NCIC CTG and Scottish Intergroup Trial. Proc. AACR 34, Abstract no 1394.

    Google Scholar 

  30. du Bois, A., Richter, B., Warm, M., Costa, S., Bauknecht, T., Lück, H. J., (1998) Cisplatin/paclitaxel vs carboplatin/paclitaxel as 1st-line treatment in ovarian cancer. Proc. ASCO 34, Abstract no 1395.

    Google Scholar 

  31. Calvert, A. H. (1997) A review of the pharmacokinetics and pharmacodynamics of combination carboplatin/paclitaxel. Semin. Oncol. 24 S2–85-S2–90.

    Google Scholar 

  32. Markman, M., Reichman, B., Hakes, T., (1993) Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small volume residual ovarian cancer. Gynecol. Oncol. 50, 100–104.

    Article  PubMed  CAS  Google Scholar 

  33. Alberts, D. S., Liu, P. Y., Hannigan, E. V., O’Toole, R., Williams, S. D., Young, J. A., (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 335, 1950–1955.

    Article  PubMed  CAS  Google Scholar 

  34. Martinez, J. A., Martin, G., Sanz, G. F., (1991) A phase II trial of carboplatin infusion in high-risk acute nonlymphoblastic leukemia. J. Clin. Oncol. 9, 39–43.

    PubMed  CAS  Google Scholar 

  35. Meyers, F. J., Welborn, J., Lewis, J. P., (1989) Infusion carboplatin treatment of relapsed and refractory acute leukaemia: evidence of efficacy with minimal extramedullary toxicity at intermediate doses. J. Clin. Oncol. 7, 173–178.

    PubMed  CAS  Google Scholar 

  36. Gaynon, P. S. (1994) Carboplatin in pediatric malignancies. Semin. Oncol. 21 (Suppl 12), 65–76.

    Google Scholar 

  37. Smith, I. E., Harland, S. J., Robinson, B. A., (1985) Carboplatin: a very active new cisplatin analogue in the treatment of small cell lung cancer. Cancer Treat. Rep. 69, 43–46.

    PubMed  CAS  Google Scholar 

  38. Skarlos, D. V., Samantas, E., Kosmidis, P., Fountzilas, G., Angelidou, M., Palamidas, P., (1994) Randomised comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group Study. Ann. Oncol. 5, 601–607.

    PubMed  CAS  Google Scholar 

  39. Smith, I. E., Perrin, T. J., Ashley, S. A., Woodiwiss, J., Forgeson, G. V., Yarnold, J. R., (1990) Carboplatin, etoposide, and ifosfamide as intensive chemotherapy for small-cell lung cancer. J Clin. Oncol. 8, 899–905.

    PubMed  CAS  Google Scholar 

  40. Gore, M. E., Calvert, A. H., Smith, I. E. (1987) High-dose carboplatin in the treatment of lung cancer and mesothelioma: a phase I dose escalation study. Eur. J. Cancer Clin. Oncol. 23, 1391–1397.

    Article  PubMed  CAS  Google Scholar 

  41. Klastersky, J., Sculier, J. P., Lacroix, H. (1990) A randomised study comparing cisplatin or carboplatin plus etoposide in patients with advanced non-small lung cancer: European Organisation for Research and Treatment of Cancer protocol 07861. J. Clin. Oncol. 8, 1556–1562.

    PubMed  CAS  Google Scholar 

  42. Non-Small Cell Lung Cancer Collaborative Group. (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311, 899–909.

    Google Scholar 

  43. Bunn, P. A. Jr., and Kelly K. (1998) New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin. Cancer Res. 4, 1087–1100.

    PubMed  CAS  Google Scholar 

  44. Bunn, P. A. Jr. (1996) The North American experience with paclitaxel combined with cisplatin or carboplatin in lung cancer. Sem. Oncol. 23 (Suppl 16), 18 – 25.

    Google Scholar 

  45. Belani, C. E, Natale, R. B., Lee, J. S., Socinski, M., Robert, E, Waterhouse, D., (1998) Randomized phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC). Proc ASCO 34, abstract no 1751.

    Google Scholar 

  46. Dillman, R. O., Seagren, S. L., Propert, K. J., (1990) A randomised trial of induction chemotherapy and high-dose radiation therapy in stage III non-small cell lung cancer. N. Engl. J. Med. 323, 940–945.

    Google Scholar 

  47. Schaake-Koning, C., Van Den Bogaert, W., Dalesio, O., (1992) Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N. Engl. J. Med. 326, 524–530.

    Article  PubMed  CAS  Google Scholar 

  48. Belani, C. P. and Aisner, J. (1994) Combined chemotherapy and radiation in locally advanced non-small cell lung cancer. Semin. Oncol. 21 (Suppl 6), 79–90.

    Google Scholar 

  49. Rosell, R., Gomez-Codina, J., Camps, C., Maestre, J., Padille, J., Canto, A., (1994) A randomised trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N. Eng. J. Med. 330, 153–158.

    Google Scholar 

  50. Merlano, M., Vitale, V., Rosso, R., (1992) Treatment of advanced squamous cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N. Engl. J. Med. 327, 1115–1121.

    Article  PubMed  CAS  Google Scholar 

  51. Haselow, R. E., Warshaw, M. G., Okin, M. M., (1990) Radiation alone versus radiation plus weekly low-dose cis-platinum in unresectable cancer of the head and neck, in Head and Neck Cancer, vol 2, (Fee, W. E., Jr., Goepfert, H., Johns, M. E., eds.), Decker, Toronto, pp. 279–281.

    Google Scholar 

  52. Marcial, V. A., Pajak, T. E, Mohiuddin, M., (1990) Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of the head and neck. Cancer 66, 1861–1868.

    Article  PubMed  CAS  Google Scholar 

  53. Laramore, G. E., Scott, C. B., Al-Sarraf, M., (1992) Adjuvant chemotherapy for resectable squamous cell carcinoma of the head and neck: report on Intergroup Study 0034. Int. J. Radiat. Oncol. Biol. Phys. 23, 705–713.

    Article  PubMed  CAS  Google Scholar 

  54. Zamboglou, N., Schnabel, T., Kolotas, C., (1994) Carboplatin and radiotherapy in the treatment of head and neck cancer: six years’ experience. Sem. Oncol. 21 (Suppl 12), 45–53.

    Google Scholar 

  55. Raabe, N. K., Fossa, S. D., and Paro G. (1989) Phase II study of carboplatin in locally advanced and metastatic transitional cell carcinoma of the urinary bladder. Br. J. Urol. 64, 604–607.

    Article  PubMed  CAS  Google Scholar 

  56. Loehrer, R J., Einhorn, L. H., Elson, R. J., (1992) A randomised comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol. 10, 1066–1073.

    PubMed  Google Scholar 

  57. Petrioli, R., Frediani, B., Manganelli, A., Barbanti, G., De Capua, B., De Lauretis, A., (1996) Comparison between a cisplatin-containing regimen and a carboplatin containing regimen for recurrent or metastatic bladder cancer patients. A randomised phase II study. Cancer 77, 344–351.

    Article  PubMed  CAS  Google Scholar 

  58. Waxman, J., and Wasan, H. (1994) Platinum based chemotherapy for bladder cancer. Semin. Oncol. 21 (Suppl 12), 54–60.

    Google Scholar 

  59. Lokich, J. and Anderson, N. (1998) Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann. Oncol. 9, 13–21.

    Article  PubMed  CAS  Google Scholar 

  60. Hainsworth, J. D., Johnson, D. H., Greco, F. A. (1992) Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. J. Clin. Oncol. 10, 912–922.

    Google Scholar 

  61. Nichols, C. R., Andersen, J., Lazarus, H. M., (1992) High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Co-operative Oncology Group study. J. Clin. Oncol. 10, 558–563.

    PubMed  CAS  Google Scholar 

  62. Motzer, R., Gulati, S., Crown, J., (1992) High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors: early intervention is better tolerated. Cancer 69, 550–556.

    Article  PubMed  CAS  Google Scholar 

  63. Aghajanian, C., Fennelly, D., Shapiro, F., (1998) Phase II study of “dose-dense” high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer. J. Clin. Oncol. 16, 1852–1860.

    PubMed  CAS  Google Scholar 

  64. Crown, J., Kritz, A., Vandat, L., (1993) Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer. J. Clin. Oncol. 11, 1144–1149.

    PubMed  CAS  Google Scholar 

  65. Cascinu, S., Cordella, L., Del Ferro, E., Fronzoni, M., and Catalano, G., (1995) Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomised double-blind placebo-controlled trial. J. Clin. Oncol. 13, 26–32.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Martin S. Highley
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Hilary Calvert
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. CRC Centre for Cancer Therapeutics, The Institute of Cancer Research, UK

    Lloyd R. Kelland

  2. Department of Chemistry, Virginia Commonwealth University, USA

    Nicholas P. Farrell

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Science+Business Media New York

About this chapter

Cite this chapter

Highley, M.S., Calvert, A.H. (2000). Clinical Experience with Cisplatin and Carboplatin. In: Kelland, L.R., Farrell, N.P. (eds) Platinum-Based Drugs in Cancer Therapy. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-012-4_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-012-4_8

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-091-5

  • Online ISBN: 978-1-59259-012-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation